Affiliation:
1. Department of Gynecologic Oncology, MD Anderson Cancer Center at Cooper University Hospital, Camden, NJ 08103, USA
2. Cooper Medical School of Rowan University, Camden, NJ 08103, USA
3. Cooper Research Institute, Cooper University Healthcare, Camden, NJ 08103, USA
Abstract
High mortality rates in ovarian cancer have been linked to recurrence, metastasis, and chemoresistant disease, which are known to involve not only genetic changes but also epigenetic aberrations. In ovarian cancer, adipose-derived stem cells from the omentum (O-ASCs) play a crucial role in supporting the tumor and its tumorigenic microenvironment, further propagating epigenetic abnormalities and dissemination of the disease. Epigallocatechin gallate (EGCG), a DNA methyltransferase inhibitor derived from green tea, and Indole-3-carbinol (I3C), a histone deacetylase inhibitor from cruciferous vegetables, carry promising effects in reprograming aberrant epigenetic modifications in cancer. Therefore, we demonstrate the action of these diet-derived compounds in suppressing the growth of 3D ovarian cancer spheroids or organoids as well as post-treatment cancer recovery through proliferation, migration, invasion, and colony formation assays when compared to the synthetic epigenetic compound Panobinostat with or without standard chemotherapy. Finally, given the regulatory role of the secretome in growth, metastasis, chemoresistance, and relapse of disease, we demonstrate that natural epigenetic compounds can regulate the secretion of protumorigenic growth factors, cytokines, extracellular matrix components, and immunoregulatory markers in human ovarian cancer specimens. While further studies are needed, our results suggest that these treatments could be considered in the future as adjuncts to standard chemotherapy, improving efficiency and patient outcomes.
Funder
Camden Health Research Initiative
Subject
Molecular Biology,Biochemistry
Reference71 articles.
1. American Cancer Society (2023, January 05). Cancer Statistics Center. Available online: http://cancerstatisticscenter.cancer.org.
2. National Comprehensive Cancer Network (2023, January 10). Ovarian Cancer including Fallopian Tube Cancer and Primary Peritoneal Cancer (Version 1.2023). Available online: http://www.nccn.org/professionals/physician_gls/pdf/ovariancancer.pdf.
3. Ovarian cancer statistics, 2018;Torre;CA Cancer J. Clin.,2018
4. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries;Bray;CA Cancer J. Clin.,2018
5. First-line treatment of advanced ovarian cancer: Current research and perspectives;Marchetti;Expert Rev. Anticancer. Ther.,2010
Cited by
2 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献